Although several novel compounds, such as trastuzumab deruxtecan (T-DXd, DS-8201) and poziotinib, have emerged in recent years, increasing the objective response rate (ORR) to approximately 50% for patients with HER2-mutant NSCLC (8, 9), there is currently no approved targeted therapy for HER2-amplified LUAD. Here, ERBB2 is linked to non-small cell lung carcinoma.